iCAD (NASDAQ:ICAD) Stock Crosses Above 200 Day Moving Average – Should You Sell?

iCAD, Inc. (NASDAQ:ICAD)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.59 and traded as high as $1.97. iCAD shares last traded at $1.83, with a volume of 138,448 shares traded.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised iCAD from a “sell” rating to a “hold” rating in a research note on Thursday, November 21st.

iCAD Price Performance

The company has a fifty day moving average price of $1.82 and a 200 day moving average price of $1.59. The company has a market cap of $54.94 million, a PE ratio of -15.92 and a beta of 1.40.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in iCAD stock. Essex LLC acquired a new position in iCAD, Inc. (NASDAQ:ICAD) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 137,963 shares of the technology company’s stock, valued at approximately $216,000. Essex LLC owned approximately 0.52% of iCAD at the end of the most recent quarter. Hedge funds and other institutional investors own 24.61% of the company’s stock.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.